Age-related macular degeneration (nAMD) with type I macular neovascularization (MNV)
Conditions
Interventions
Observation group:NA
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
50 Years to No maximum
Inclusion criteria
Inclusion criteria: (1)Signed informed consent; (2)Age>= 50 years at the time of informed consent (or at the time of the first dose of faricimab, whichever occurs first) ; (3)Chinese female and male patients, who have been diagnosed with nAMD with immature or mature type I MNV (serous or multilayered pigment epithelial detachment associated with NV tissue in the sub-RPE on OCT, and identified as type I MNV on OCTA) ; (4)Already received at least one dose of faricimab; (5)Never received any anti-VEGF therapy before the first dose of faricimab; (6)Patients were able to cooperate with the treatment process and the 12-month follow-up period.
Exclusion criteria
Exclusion criteria: (1)Active ocular inflammation or suspected/active ocular infection in either eye. (2)Presence of any RPE tear, subretinal fibrosis, or atrophy in the study eye. (3)History of vitrectomy in the study eye. (4)Have other retinal vascular disease other than nAMD or ocular disease affecting visual acuity and fundus observation in the study eye. (5)PDT/TTT within the previous 90 days (6)Patients taking systemic concomitant medications (e.g., hormones, anti-VEGF agents) or other potentially retinotoxic agents that may affect the efficacy of faricimab. (7)Patients who are participating in any other interventional clinical study. (8)For patients who had received faricimab prior to enrollment: Patient unable to provide clinical data (visual acuity, OCT, and OCTA images) 2 weeks (14 days) prior to receiving initial faricimab injection; Received any other anti-VEGF therapy in the study eye after the administration of faricimab.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of patients with MNV maturity improved on OCTA; | — |
Secondary
| Measure | Time frame |
|---|---|
| Visual Acuity;Changes in imaging indicators; | — |
Countries
China
Contacts
Public ContactMeixia Zhang
West China Hospital of Sichuan University
Outcome results
None listed